Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Exicure Inc XCUR

Healthcare Biotechnology
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:XCUR)

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Business Wire 3 days ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Business Wire February 5, 2024

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Business Wire November 28, 2023

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Business Wire August 23, 2023

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Business Wire August 11, 2023

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Business Wire July 14, 2023

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Business Wire May 26, 2023

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Business Wire May 19, 2023

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Business Wire May 4, 2023
View More News ››

Opinion & Analysis (NDAQ:XCUR)

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Streetwise Reports November 15, 2019
View More Opinion ››

Bullboard Posts (NDAQ:XCUR)

Be the first to post on this bullboard.

SKRR Exploration Inc.

SKRR Exploration Inc.

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The ...
View More »